Guillermo Garcia‐Manero

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 97 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00192-7

N/A

5.0DataRank · unranked

178 citations

Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado +13 more

Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

Blood Cancer Discovery(2022)10.1158/2643-3230.bcd-21-0177

N/A

3.4DataRank · unranked

75 citations

David M. Swoboda, Uri Greenbaum, Junsheng Ma, Romil Patel, Kartik Devashish +34 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Nature Medicine(2022)10.1038/s41591-022-01696-4

N/A

2.2DataRank · unranked

83 citations

Hui Yang, Feiyang Ma, Guillermo Montalban‐Bravo, Natthakan Thongon, Valentina Marchica +33 more

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

American Journal of Hematology(2023)10.1002/ajh.27070

N/A

1.6DataRank · unranked

48 citations

Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S. Chien +19 more

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01476-8

N/A

1.3DataRank · unranked

51 citations

Muharrem Müftüoğlu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban‐Bravo +22 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Nature Cancer(2024)10.1038/s43018-024-00811-3

N/A

0.878DataRank · unranked

37 citations

Divij Verma, Natalia Baran, Tushar D. Bhagat, Anna Skwarska, Alessia Lodi +42 more

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Blood Cancer Journal(2021)10.1038/s41408-021-00557-6

N/A

0.692DataRank · unranked

100 citations

Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning +16 more

Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations

Blood(2024)10.1182/blood.2024025023

N/A

0.557DataRank · unranked

40 citations

Emma M. Groarke, Natthakan Thongon, Juan José Rodríguez‐Sevilla, Luiz Fernando Bazzo Catto, Marena R. Niewisch +37 more

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

American Journal of Hematology(2023)10.1002/ajh.26997

N/A

0.442DataRank · unranked

18 citations

Hagop M. Kantarjian, Naszrin Arani, Uday Popat, Álex Bataller, Koji Sasaki +19 more

Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes

Nature Communications(2025)10.1038/s41467-025-58662-0

N/A

0.321DataRank · unranked

7 citations

Irene Gañán‐Gómez, Bijender Kumar, Natthakan Thongon, Feiyang Ma, Kelly S. Chien +35 more

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

American Journal of Hematology(2025)10.1002/ajh.70046

N/A

0.245DataRank · unranked

4 citations

Sanam Loghavi, Alexandre Bazinet, Álex Bataller, Ian Bouligny, Naval Daver +15 more

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Haematologica(2025)10.3324/haematol.2024.286559

N/A

0.165DataRank · unranked

2 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado +19 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood(2024)10.1182/blood-2024-207413

N/A

0.104DataRank · unranked

1 citations

Jennifer Marvin‐Peek, Marina Konopleva, Gautam Borthakur, Naval Daver, Hussein A. Abbas +21 more

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.04.283598

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Elias Jabbour, Carlos E. Bueso‐Ramos, Yue Wei +14 more

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

Leukemia(2021)10.1038/s41375-021-01328-9

N/A

0DataRank · unranked

183 citations

Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji +35 more

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Nature Communications(2021)10.1038/s41467-021-26282-z

N/A

0DataRank · unranked

132 citations

Dapeng Hao, Katarzyna Tomczak, Praveen Barrodia, Jin S. Im, Patrick K. Reville +28 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Nature Communications(2021)10.1038/s41467-021-22874-x

N/A

0DataRank · unranked

117 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

The cure of leukemia through the optimist's prism

Cancer(2021)10.1002/cncr.33933

N/A

0DataRank · unranked

67 citations

Nitin Jain, Guillermo Garcia‐Manero, Mary Alma Welch, Farhad Ravandi, William G. Wierda +2 more

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood(2021)10.1182/blood.2020010483

N/A

0DataRank · unranked

43 citations

Kiyomi Morita, Sanam Loghavi, Feng Wang, Ken Furudate, Yuya Sasaki +19 more

Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications

Frontiers in Immunology(2021)10.3389/fimmu.2020.590494

N/A

0DataRank · unranked

43 citations

Ajay Sheshadri, Vickie R. Shannon, Dimitrios P. Kontoyiannis, Hagop M. Kantarjian, Guillermo Garcia‐Manero +20 more

Hematopoiesis under telomere attrition at the single-cell resolution

Nature Communications(2021)10.1038/s41467-021-27206-7

N/A

0DataRank · unranked

36 citations

Feiyang Ma, Andrea Santoni, Matteo Marchesini, Elena Fiorini, Ashley Rose +20 more

Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned

Blood Reviews(2021)10.1016/j.blre.2021.100851

N/A

0DataRank · unranked

35 citations

Uwe Platzbecker, Pierre Fenaux, Guillermo Garcia‐Manero, Thomas W. LeBlanc, Bhumika J. Patel +3 more

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

Cancer(2021)10.1002/cncr.33745

N/A

0DataRank · unranked

32 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Faezeh Darbaniyan, Elias Jabbour, Carlos E. Bueso‐Ramos +13 more

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia(2021)10.1038/s41375-021-01240-2

N/A

0DataRank · unranked

31 citations

Danielle Hammond, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J. Short +15 more

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes

Frontiers in Immunology(2021)10.3389/fimmu.2021.659625

N/A

0DataRank · unranked

17 citations

Patrick K. Reville, Xianli Jiang, Hui Yang, Alexandre Reuben, Jin S. Im +6 more

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

Blood Cancer Journal(2021)10.1038/s41408-021-00446-y

N/A

0DataRank · unranked

10 citations

Guillermo Montalban‐Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour +26 more

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Cancer(2021)10.1002/cncr.33409

N/A

0DataRank · unranked

10 citations

Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Xuemei Wang, Elias Jabbour +16 more

Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1881512

N/A

0DataRank · unranked

2 citations

Megan Othus, Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba, Roland B. Walter +1 more

Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2021)10.1038/s41467-021-23280-z

N/A

0DataRank · unranked

7 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

Contemporary outcomes for adults with AML requiring ICU admission.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7025

N/A

0DataRank · unranked

4 citations

Koji Sasaki, Alexis Geppner, Fadi Haddad, Shehab Mohamed, Daniel Rivera +15 more

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Blood(2022)10.1182/blood.2021014956

N/A

0DataRank · unranked

140 citations

Veronica Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang +20 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3

N/A

0DataRank · unranked

117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Advances(2022)10.1182/bloodadvances.2022008316

N/A

0DataRank · unranked

56 citations

Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia +20 more

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01229-z

N/A

0DataRank · unranked

32 citations

Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron +18 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0DataRank · unranked

23 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

Aberrant DNA hydroxymethylation reshapes transcription factor binding in myeloid neoplasms

Clinical Epigenetics(2022)10.1186/s13148-022-01297-5

N/A

0DataRank · unranked

5 citations

Tingting Hong, Yue Wei, Lei Guo, Minjung Lee, Hui Yang +10 more

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Blood Advances(2022)10.1182/bloodadvances.2021006689

N/A

0DataRank · unranked

1 citations

Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short +6 more

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management

American Journal of Hematology(2023)10.1002/ajh.26984

N/A

0DataRank · unranked

202 citations

Guillermo Garcia‐Manero

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

American Journal of Hematology(2023)10.1002/ajh.27161

N/A

0DataRank · unranked

48 citations

Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl +22 more

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

Cancers(2023)10.3390/cancers15071983

N/A

0DataRank · unranked

33 citations

Amber Gibson, Jiasen He, David McCall, Michael Roth, César Núnêz +23 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1429

N/A

0DataRank · unranked

23 citations

Warren Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia‐Manero +19 more

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

Cancer(2023)10.1002/cncr.34728

N/A

0DataRank · unranked

20 citations

Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan +12 more

Association between bariatric surgery and outcomes in chronic myeloid leukemia

Cancer(2023)10.1002/cncr.34725

N/A

0DataRank · unranked

11 citations

Hagop M. Kantarjian, Aram Bidikian, Elias Jabbour, Nicholas J. Short, Jing Ning +10 more

Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept

Frontiers in Immunology(2023)10.3389/fimmu.2023.1249511

N/A

0DataRank · unranked

9 citations

Naval Daver, Myrna C. B. Godoy, Girish S. Shroff, Carol C. Wu, Luis F. Torre-Sada +19 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

Research Square(2023)10.21203/rs.3.rs-2518774/v1

N/A

0DataRank · unranked

7 citations

Courtney D. DiNardo, Tushar D. Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena +38 more

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.22.529457

N/A

0DataRank · unranked

1 citations

Feiyang Ma, Pamela Lockyer, Natalia Baran, Jintan Liu, C. Ellen Jackson +27 more

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood(2023)10.1182/blood-2023-190400

N/A

0DataRank · unranked

1 citations

Zongrui Li, Abhishek Maiti, Tomoyuki Tanaka, Hidetaka Uryu, Ken Furudate +21 more

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

medRxiv(2023)10.1101/2023.12.06.23299616

N/A

0DataRank · unranked

1 citations

Nicholas J. Short, Hagop M. Kantarjian, Ti‐Cheng Chang, Pankaj S. Ghate, Chunxu Qu +17 more

Data from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

(2023)10.1158/2643-3230.c.6550812.v1

N/A

0DataRank · unranked

0 citations

David M. Swoboda, Uri Greenbaum, Junsheng Ma, Romil Patel, Kartik Devashish +34 more

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Blood(2023)10.1182/blood-2023-182841

N/A

0DataRank · unranked

0 citations

Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour +12 more

BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML

Science Translational Medicine(2024)10.1126/scitranslmed.adp0004

N/A

0DataRank · unranked

31 citations

Anand K. Singh, Rafet Başar, Nadima Uprety, Ye Li, Huihui Fan +45 more

Advancing drug development in myelodysplastic syndromes

Blood Advances(2024)10.1182/bloodadvances.2024014865

N/A

0DataRank · unranked

12 citations

Kathy L. McGraw, Lea Cunningham, Nina Kim, Emily Y. Jen, Katherine R. Calvo +17 more

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Haematologica(2024)10.3324/haematol.2023.284078

N/A

0DataRank · unranked

15 citations

Lucia Masárová, Naveen Pemmaraju, Sharon Bledsoe, Naval Daver, Elias Jabbour +19 more

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101585

N/A

0DataRank · unranked

14 citations

Natthakan Thongon, Juan José Rodríguez‐Sevilla, Feiyang Ma, Irene Gañán‐Gómez, Hui Yang +16 more

Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

Nature Communications(2024)10.1038/s41467-024-46424-3

N/A

0DataRank · unranked

10 citations

Irene Gañán‐Gómez, Feiyang Ma, Kelly S. Chien, Mónica Del Rey, Sanam Loghavi +13 more

Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

Leukemia(2024)10.1038/s41375-024-02143-8

N/A

0DataRank · unranked

6 citations

Andrew H. Wei, Sumithra J. Mandrekar, Ing Soo Tiong, Chong Chyn Chua, Tse‐Chieh Teh +24 more

Artificial Intelligence Assessment of Chest Radiographs for COVID-19

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.11.013

N/A

0DataRank · unranked

2 citations

Guillermo Garcia‐Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G. Wierda +14 more

Accurate identification of locally aneuploid cells by incorporating cytogenetic information in single cell data analysis

Scientific Reports(2024)10.1038/s41598-024-75226-2

N/A

0DataRank · unranked

1 citations

Ruoxing Li, Irene Gañán‐Gómez, Hussein A. Abbas, Guillermo Garcia‐Manero, Wei Sun +1 more

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood(2024)10.1182/blood-2024-203706

N/A

0DataRank · unranked

5 citations

Jayastu Senapati, Sanam Loghavi, Patrick K. Reville, Bofei Wang, Tapan M. Kadia +21 more

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Blood(2024)10.1182/blood-2024-211599

N/A

0DataRank · unranked

3 citations

H. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo +13 more

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Blood(2024)10.1182/blood-2024-209558

N/A

0DataRank · unranked

2 citations

Wei‐Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero +12 more

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood(2024)10.1182/blood-2024-208890

N/A

0DataRank · unranked

1 citations

Kelly S. Chien, Sanam Loghavi, Rashmi Kanagal‐Shamanna, Anuya Natu, Mark E. Gurney +22 more

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood(2024)10.1182/blood-2024-210779

N/A

0DataRank · unranked

0 citations

Hussein A. Abbas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo +19 more

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood(2024)10.1182/blood-2024-205186

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero +15 more

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Blood(2024)10.1182/blood-2024-208106

N/A

0DataRank · unranked

0 citations

Koichi Saeki, Hiroshi Haeno, Chiraag D. Kapadia, Ken Furudate, Jyoti Nangalia +35 more

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0229

N/A

0DataRank · unranked

15 citations

Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi +21 more

Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

Nature Genetics(2025)10.1038/s41588-025-02235-w

N/A

0DataRank · unranked

11 citations

Koichi Saeki, Hiroshi Haeno, Chiraag D. Kapadia, Ken Furudate, Jyoti Nangalia +39 more

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

Cancer Cell(2025)10.1016/j.ccell.2025.03.007

N/A

0DataRank · unranked

5 citations

Abdullah Mahmood Ali, Rossella Labella, Brygida Bisikirska, Álvaro Cuesta‐Domínguez, Paraskevi Vgenopoulou +29 more

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70171

N/A

0DataRank · unranked

3 citations

Guojun Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Alexandre Bazinet +20 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203

Leukemia(2025)10.1038/s41375-024-02512-3

N/A

0DataRank · unranked

0 citations

Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba, Eliana Dietrich, Suravi Raychaudhuri +4 more

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2020003120

N/A

0DataRank · unranked

182 citations

Guillermo Montalban‐Bravo, Hyunsoo Hwang, Jing Ning, Miguel Franquiz, Rashmi Kanagal‐Shamanna +12 more

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy

Blood Neoplasia(2025)10.1016/j.bneo.2025.100129

N/A

0DataRank · unranked

0 citations

Megan Othus, Mary‐Elizabeth M. Percival, Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba +2 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2020)10.1038/s41467-020-19119-8

N/A

0DataRank · unranked

391 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Blood Advances(2020)10.1182/bloodadvances.2019001101

N/A

0DataRank · unranked

133 citations

Rashmi Kanagal‐Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki +17 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Leukemia(2020)10.1038/s41375-020-0778-0

N/A

0DataRank · unranked

52 citations

Srđan Verstovšek, Jörge E. Cortes, Susan Tse, Yvonne Gasior, Nitin Jain +19 more

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32623

N/A

0DataRank · unranked

21 citations

Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva +11 more

Germline DNMT3A mutation in familial acute myeloid leukaemia

Epigenetics(2020)10.1080/15592294.2020.1809871

N/A

0DataRank · unranked

10 citations

Hannah C. Beird, Marcos R. Estecio, Swanand Hardikar, Koichi Takahashi, Sarah A. Bannon +12 more

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001156

N/A

0DataRank · unranked

43 citations

Keyur P. Patel, Maher Albitar, Miguel Franquiz, Rajyalakshmi Luthra, Rashmi Kanagal‐Shamanna +15 more

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Blood Cancer Journal(2020)10.1038/s41408-020-0329-y

N/A

0DataRank · unranked

36 citations

Hagop M. Kantarjian, Rashmi Kanagal‐Shamanna, Koji Sasaki, Farhad Ravandi, Jörge E. Cortes +15 more

Long‐term results of frontline dasatinib in chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32627

N/A

0DataRank · unranked

34 citations

Jörge E. Cortes, Keyur P. Patel, Lucia Masárová, Gautam Borthakur, Farhad Ravandi +14 more

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia

JCO Oncology Practice(2020)10.1200/jop.19.00133

N/A

0DataRank · unranked

23 citations

Megan Othus, Guillermo Garcia‐Manero, Min Fang, Jerald P. Radich, David A. Rizzieri +24 more

Clinical value of event-free survival in acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001150

N/A

0DataRank · unranked

7 citations

Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Konopleva +16 more

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

American Journal of Hematology(2020)10.1002/ajh.25991

N/A

0DataRank · unranked

6 citations

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia +13 more

Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.02.07.925743

N/A

0DataRank · unranked

67 citations

Feng Wang, Katharina Jahn, Jack Kuipers, Yuanqing Yan, Jairo Matthews +22 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.27.357111

N/A

0DataRank · unranked

20 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519

N/A

0DataRank · unranked

8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.03.278309

N/A

0DataRank · unranked

3 citations

Dapeng Hao, Katarzyna Tomczak, Praveen Barrodia, Jin S. Im, Patrick K. Reville +22 more